Minerva Neurosciences Explores Klotho-Based Therapies for Neurodegenerative Diseases at Upcoming Conference

Innovative Focus on Klotho-based Therapeutics in Neurodegenerative Disease Treatment

Klotho Neurosciences, Inc., a biotechnology company dedicated to developing Klotho-based therapeutics, is poised to make a significant impact in the realm of neurodegenerative disease treatment. The company is set to participate in the inaugural Klotho Conference & Scientific Seminar on September 15-16, 2025, at the UC-Irvine Beal Applied Innovation Center. This event marks a pivotal moment for Klotho, as it is the first conference solely focused on the future of Klotho-based therapies and diagnostics. Dr. Joseph Sinkule, the CEO and Chairman of Klotho, will engage with key stakeholders, including investors and potential partners, to highlight the company's innovative approach to biogenetics.

At the conference, Dr. Sinkule will be accompanied by esteemed scientific advisors and inventors, Dr. Miguel Chillon and Dr. Assumpcio Bosch. Together, they will present groundbreaking research on Klotho gene therapy, specifically targeting debilitating conditions such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease. The Klotho gene, known for its associations with longevity and age-related disorders, serves as a cornerstone of the company’s therapeutic strategy. Klotho’s proprietary technology leverages a patented form of the "anti-aging" human Klotho gene (s-KL), which aims to develop disease-modifying cell and gene therapies. This innovative approach could reshape treatment methodologies for neurodegenerative and age-related disorders, offering new hope for patients suffering from these conditions.

Klotho’s commitment to advancing the field of biogenetics is further demonstrated by its diverse portfolio, which includes proprietary cell and gene therapy programs that utilize DNA and RNA as therapeutics. Additionally, the company is developing genomics-based diagnostic assays to enhance the understanding and treatment of neurodegenerative diseases. The management team boasts extensive experience in biopharmaceutical product development and commercialization, positioning Klotho as a significant player in the biotechnology landscape. The conference will not only serve as a platform for disseminating research but also as an opportunity for Klotho to forge collaborations that could accelerate the development and commercialization of its innovative therapies.

In conjunction with its participation in the Klotho Conference, Klotho Neurosciences emphasizes that forward-looking statements regarding the company’s future operations are subject to various risks and uncertainties. These factors could result in actual outcomes differing from current expectations. The company encourages interested parties to reach out for potential collaborations during the event, further underscoring its commitment to developing transformative therapies for neurodegenerative diseases. As Klotho Neurosciences continues to advance its research and development efforts, it remains at the forefront of innovation in addressing the challenges posed by age-related disorders.